Gili Hart is a biotech executive serving as the CEO of SpilSense (2020 to the present). Dr. Hart has extensive experience in preclinical, clinical and global regulatory strategic planning (5 INDS; BLA), partnering with large-pharma, and financing (fundraising of $50M). In addition, she brings broad experience in managing critical global programs ranging from discovery phase through global Phase 3 clinical trials (5 Phase 1; 4 phase 2 and 3 phase 3 studies). Prior to SpliSense, Dr. Hart served as CEO of Mitoconix Bio (2017-2019). She also served as General Manager of OPKO Biologics (2014-2017) and as VP of Pre-clinical and Clinical development at PROLOR Biotech during 2007-2013. During 2005-2007, Dr. Hart was a Research Fellow at Yale University's School of Medicine. She received cum laude PhD and MSc degrees from the Weizmann institute of science and graduated summa cum laude from the Technion with a Biotechnology Engineering degree.